For the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE), as per Health Canada indication.
Indicated for the induction and maintenance of clinico-pathological remission in adults with eosinophilic esophagitis (EoE).
Reimburse with clinical criteria and/or conditions
The requested reimbursement criteria are provided by the applicant and do not
the views of CADTH. Reimbursement criteria from CADTH will be documented in the final
recommendation, if applicable.
Call for patient/clinician input open
Call for patient/clinician input closed
- Patient input submission received from the EOS Network (formerly FABED ), Food Allergy Canada and the Gastrointestinal Society
Draft CADTH review report(s) provided to sponsor for comment
Deadline for sponsors comments
- Submission temporarily suspended pending receipt of information
- Additional information has been received and the temporary suspension of the review has been lifted
CADTH responses on draft review report(s) provided to sponsor
Expert committee meeting (initial)
Draft recommendation issued to sponsor
Draft recommendation posted for stakeholder feedback
End of feedback period
Final recommendation issued to sponsor and drug plans
Final recommendation posted
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)